AstraZeneca Allemansfond

The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca. For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab. The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

Performance

rfor	mance					04.07.20	04.07.2025	
TD	4 1.	446	0 *	4	-	40		


YTD	1 week	1 mth.	3 mån	1 year	5 years	10 years
-0.31%	1.36%	-0.52%	3.66%	-5.74%	80.20%	221.53%

Average performance

Average. perf.	2 years	3 years	5 years	10 years
Fund ¹	2.18%	8.86%	12.39%	12.49%
Index ²	3.66%	8.62%	10.77%	-

¹ Calculated on the fund's monthly closing price

Five years performance



Portfolio



Portfolio manager comments — Q1 2025

Fund performance was favorable during Q1 2025 and the fund rose 1.6% in SEK. Astra Zeneca, Volvo and SEB were the strongest contributors to fund returns. Astra Zeneca benefited when the investigation in China appeared to have less of an effect than expected. Volvo performed positively after a strong quarterly report and SEB has, in line with the rest of the bank sector, benefited in part from its domestic exposure.

Beijer Ref, Autoliv and Thule had the most negative impact during the period. Beijer Ref posted weak performance in line with the manufacturing sector, while Autoliv was affected by concerns about tariffs between the US and Mexico. Thule was weighed down by the market's fears that the Q1 report would be below expectations.

Fund manager



Ulrika Orstadius

Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.

Main cate	egory	Equity Fund
Risk		4
Rate		3848.41 (04.07.2025)
Reporting	g Currency	SEK
Price/Tra	de	Daily
Total Rat	ing™	***
	_	
Minimum	n investment	0 SEK
Monthly	savings	0 SEK
Traded o	n the Internet	No
Manager	ment Fee	0.9%
Entry cha	arge	0%
Exit char	ge	0%
Fund ass	sets	4,678 MSEK
Distributi unit	on per fund	-
Distributi	on date	-

Fund, date of launch 01 04 1984 Share class, date of 01.04.1984

Largest holdings

	9
AstraZeneca PLC	43.90%
Volvo AB Class B	6.06%
Sandvik AB	5.29%
Hexagon AB Class B	4.68%
Essity AB Class B	4.57%
Beijer Ref AB Class B	4.08%
Skandinaviska Enskilda I Class A	Banken AB 3.77%
Autoliv Inc SEDR	3.34%
Epiroc AB Ordinary Share	es - Class A 3.06%
Sweco AB Class B	2.87%

² Benchmark index: SIX SRI Sweden Index GI (60%), AstraZeneca (40%). The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

The fund increased the holding in Astra Zeneca during the quarter as part of a rebalancing in the portfolio. Sandvik and Essity were also increased, due to our assessment of attractive valuations. At the same time, we decreased in Volvo due to greater uncertainty and chose to take profits in Handelsbanken during the quarter.

We continued to focus on investee companies that have sustainable business models and competitive offers with sustainable growth.

As of: 16.04.2025

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.

The fund's fact sheet, risk level, fund rules and prospectus are available at www.handelsbanken.se/funds. Handelsbanken does not assume liability for any errors in the information.

www.handelsbanken.se/funds

Handelsbanken